Reading China’s TGCT market through Beijiemai: hospitals first, reimbursement still open
China approved Abbisko’s CSF-1R inhibitor Beijiemai (pimicotinib, 02256.HK) first and Merck KGaA launched in tertiary hospitals, while list price and NRDL status remain open.